Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Hungerford

Orthopaedic Surgery Baltimore, MD Medical Doctor

NPI 1710955448 CMS profile 1152564

5601 Loch Raven Blvd, Pob-G1, Baltimore, MD 21239

Open in the dashboard

General payments

$98,174

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$54,497

5 holdings reported · through program year 2025

Research they led as principal investigator

$7,600 paid to institutions, not to them · program year 2023

Through program year 2025, Marc Hungerford of Baltimore, MD is reported in the CMS Open Payments database as having received $98,174 across 100 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,600 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $54,497 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,175 28
2024 General $9,917 13
2023 General $14,670 16
2022 General $18,839 21
2021 General $7,784 11
2020 General $1,381 4
2019 General $408 7
2021 Ownership $25,263 1
2020 Ownership $25,263 1
2019 Ownership $3,971 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Hungerford
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Marc Hungerford were reported at $45,175. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Marc Hungerford Orthopaedic Surgery median Middle half National median
2019 $408 $644 $140–$2,844 $163
2020 $1,381 $312 $75–$1,860 $114
2021 $7,784 $520 $117–$2,495 $132
2022 $18,839 $598 $128–$2,731 $149
2023 $14,670 $461 $128–$2,264 $160
2024 $9,917 $497 $134–$2,475 $164
2025 $45,175 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ortho Development Corporation $95,492 75 payments
  2. Medical Device Business Services, Inc. $1,671 8 payments
  3. Zimmer Biomet Holdings, Inc. $574 8 payments
  4. Spineology Inc. $187 1 payment
  5. Stryker Corporation $114 2 payments
  6. Smith+Nephew, Inc. $40 1 payment
  7. Medtronic, Inc. $35 1 payment
  8. Maquet Cardiovascular U.S. Sales, L.L.C. $21 1 payment
  9. Dynasplint Systems Inc. $19 1 payment
  10. Pacira Pharmaceuticals Incorporated $14 1 payment
  11. Other $9 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $36,170 19 payments
  2. Royalty or License $27,280 16 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $22,000 4 payments
  4. Travel and Lodging $9,766 20 payments
  5. Food and Beverage $2,958 41 payments
Products named General payments · program years 2019–2025
  1. Trivicta $46,354 26 payments
  2. ATTUNE $380 6 payments
  3. Persona $374 5 payments
  4. Legend $271 3 payments
  5. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $187 1 payment
  6. BKS Revision $184 1 payment
  7. Balanced Knee System $147 1 payment
  8. Entrada Hip Stem $124 2 payments
  9. EXPAREL $121 1 payment
  10. MAKO $114 2 payments
  11. Other $404 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$332,715

Of which drugs: $11,368

Medicare patients

849

Average age 74

Services billed

3,385

552 women, 297 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Diabetes 24%
Ischemic heart disease 24%
Depression 23%
Chronic kidney disease 16%
Cancer 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 28 98 $9,080
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 187 1,141 $849

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record